Live Breaking News & Updates on Ngager

Stay updated with breaking news from Ngager. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Côte d'Ivoire : Après les élections locales de 2023, Gbagbo veut engager le combat de sa réinscription sur la liste électorale

Laurent Gbagbo ce mardi à Cocody (Ph KOACI)Laurent Gbagbo, président du Parti des Peuples Africains - Côte d'Ivoire (PPA... - KOACI l'Info au Coeur de l'Afrique

Koaci , Rticle , Ctualité , Nfo , Oaci-côted-ivoire , ôted-ivoire , Olitique , ôte , D-ivoire , Près , Ocales

Innate Pharma SA: Innate Pharma Highlights Proprietary Tetra-specific ANKET NK Cell Engager IPH6501 at the EHA 2023 Congress

IPH6501 is a first-in-class tetra-specific antibody-based natural killer cell engager therapeutic, based on ANKET platform, targeting CD20 developed for the treatment of B-cell non-Hodgkin's lymphomas

France , French , Eric-vivier , Henry-wheeler , Arthur-rouill , Euronext , Company-annual-report-on-form , Nasdaq , Exchange-commission , European-hematology-association , Linkedin , French-financial-markets-authority

Innate Pharma SA: Innate Pharma Highlights Phase 1/2 Dose Escalation Safety and Preliminary Efficacy of Sanofi Developed First NK Cell Engager SAR'579 / IPH6101 in R/R AML

SAR'579/IPH6101, ANKET platform lead asset, is a trifunctional anti-CD123 NKp46×CD16 NK cell engager from a joint research collaboration between Innate Pharma and Sanofi, now under development by

France , French , Valeria-fantin , Gewinn-nur , Arthur-rouill , Henry-wheeler , Mondher-mahjoubi , Exchange-commission , Global-head-of-oncology-research-at-sanofi , Euronext , French-financial-markets-authority , Oncology-development-at-sanofi

Harpoon Therapeutics Presents Data for New ProTriTAC™ Development Candidates in TROP2- and ITGB6-expressing Solid Tumors at AACR 2023

Results support further investigation of two new ProTriTAC™ protease-activated T cell engager development candidates, with demonstrated therapeutic potential in a broad range of TROP2- and... | April 17, 2023

United-states , American , S-jack-lin , Roberth-uhl , Luke-walker , Exchange-commission , American-association-for-cancer-research , Harpoon-therapeutics-inc , Nasdaq , Preclinical-development , American-association , Cancer-research

IGM Biosciences : Announces Third Quarter 2022 Financial Results and Provides Corporate Update - Form 8-K

IGM Biosciences Announces Third Quarter 2022 Financial Results and Provides Corporate Update

- Data from T cell Engager Portfolio for Hematologic Malignancies, Including First... | November 3, 2022

Louisiana , United-states , New-orleans , American , Albert-candia , Bispecific-ig , David-pitts , Fred-schwarzer , Preclinical-sciences , Society-for-immunotherapy-of-cancer , Bucknell-university , Nasdaq

Oncopeptides AB: Oncopeptides receives 5 MSEK grant for NK-cell engager project in multiple myeloma

STOCKHOLM, Sept. 7, 2022 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq: ONCO) (Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological

United-kingdom , Germany , Norway , Stockholm , Sweden , Italy , Finland , Oslo , France , Spain , Fredrik-schjesvold , Rolf-gulliksen

Innate Pharma SA: Second Innate Pharma NK Cell Engager Selected by Sanofi as Drug Candidate for Development

IPH6401/SAR'514 is a BCMA-targeting NK cell engager using Sanofi's proprietary CROSSODILE multi-functional platform. It was developed jointly and benefits from the dual NK targeting of Innate's

France , French , Henry-wheeler , Eric-vivier , Bristol-myers-squibb , Novo-nordisk , Company-annual-report-on-form , French-financial-markets-authority , Exchange-commission , Astrazeneca , Nasdaq , Euronext

Dren Bio, Inc.: Dren Bio Announces $65 Million Series B Financing to Advance its Lead Asset into the Clinic and to Accelerate Development of New Product Candidates from its Targeted Myeloid Engager and Phagocytosis Platform

- Momentum continues to build for Dren Bio after successfully forming highly experienced senior leadership team and earlier this year announcing research collaboration and license deal with Pfizer -

Alexandria , Al-iskandariyah , Egypt , Kostenloser-wertpapierhandel , Chandrap-leo , Nenad-tomasevic , Jeff-macfarland , Andrew-schiff , Pfizer , Company-contact , Company-targeted-myeloid-engager , Mission-biocapital

Numab Therapeutics AG: Numab and 3SBio's Sunshine Guojian Expand Partnership to Develop Novel T Cell Engager NM28

Numab Therapeutics AG (Numab) and 3SBio Inc. ("3SBio", HKEX:1530) announced today that 3SBio's subsidiary Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. ("Sunshine Guojian") exercised its option

Taiwan , Shanghai , China , Hong-kong , Shenzhen , Guangdong , Shenyang , Liaoning , Italy , Zurich , Züsz , Switzerland

EssilorLuxottica : envisage des poursuites contre GrandVision

EssilorLuxottica : envisage des poursuites contre GrandVision
zonebourse.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from zonebourse.com Daily Mail and Mail on Sunday newspapers.

Netherlands , France , French , Dutch , Dutch-court , Reuters , Reporting-claudia , Essilorluxottica-bourse , Nformation , Ews , E